Alternatively, as tau and Aβ are common drug targets in AD clinical trials, a surrogate measure of synaptic dysfunction that does not directly measure the drug target levels would be a useful addition to the biomarker arsenal. This evidence concerns the gene MAPT and Alzheimer disease.